Mitochondrial Dysfunction and Insulin Resistance in Skeletal Muscle
NCT ID: NCT04558190
Last Updated: 2021-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2020-09-02
2021-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lipid infusion + MitoQ
Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by MitoQ administration and intravenous lipid infusion
Intralipid, 20% Intravenous Emulsion
Lipid infusion
MitoQ
Oral administration of MitoQ capsules
Lipid infusion + placebo
Subjects undergo a hyperinsulinemic isoglycemic clamp preceded by placebo administration and intravenous lipid infusion
Intralipid, 20% Intravenous Emulsion
Lipid infusion
Control
Subjects undergo a hyperinsulinemic isoglycemic clamp
No interventions assigned to this group
Lipid infusion + beta2-agonist
Subjects undergo a hyperinsulinemic isoglycemic clamp with intravenous infusion of lipid and salbutamol
Intralipid, 20% Intravenous Emulsion
Lipid infusion
Salbutamol
Beta2-agonist infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intralipid, 20% Intravenous Emulsion
Lipid infusion
MitoQ
Oral administration of MitoQ capsules
Salbutamol
Beta2-agonist infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting plasma glucose ≥ 5.6 mmol/L or HbA1c ≥ 5.7%
* HOMA2-IR \> 1.4
* VO2max \<45 ml/kg/min
Exclusion Criteria
* Insulin usage
* Chronic disease deemed by the study responsible medical doctor to interfere with any part of the study
* Chronic use of prescription medicine deemed by the study responsible medical doctor to interfere with any part of the study
* Smoking
40 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
mtROS-IR
Identifier Type: -
Identifier Source: org_study_id